
Thursday, June 26, 2025 8:52:33 AM
The repurchases would be conducted through open market transactions at prices of up to $0 .05c/share, with repurchased shares to be returned to Treasury and retired by the Company. The timing and amount of the purchases would be at Brookmount's discretion, in compliance with relevant Securities and Exchange Commission rules and regulations.
Brookmount's CEO Nils Ollquist said, "We have issued a vote of confidence in our Company, our stock, and our strategic plans. Since the Company now has a strong, audited balance sheet, a new credit facility and under $2 million in liabilities, we have the flexibility to take actions like this which support strong shareholder returns, as we continue exploring further strategic opportunities and enhance both the stability and growth metrics of our operations."
The Share Repurchase Authorization would not alter the company's other strategic initiatives including finalizing the payoff of outstanding convertible debt, accelerating production in Indonesia and North American operations and the completion of the PSWW acquisition and spinoff of the North American assets. The Company will retain broad discretion over the terms, prices, and factors applicable to such repurchases but anticipates commencing purchases in a timely manner.
Never argue with stupid people. They will drag you down to their level and beat you with experience.” - Mark Twain
Recent BMXI News
- Form 253G1 - • Edgar (US Regulatory) • 05/29/2025 05:51:25 PM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 04/30/2025 09:25:41 PM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 08/30/2024 04:31:45 PM
VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • FITY • Jul 8, 2025 8:30 AM